ROBUSTNESS OF THE PHOENIX BIOCHEMICAL FAILURE DEFINITION 10 YEARS AFTER COMPLETING DOSE ESCALATED RADIOTHERAPY IN A COHORT OF INTERMEDIATE RISK PROSTATE CANCER PATIENTS

Aljawi Ghufran; Busca Ionut; MacRae Robert; Eapon Libni

首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >ROBUSTNESS OF THE PHOENIX BIOCHEMICAL FAILURE DEFINITION 10 YEARS AFTER COMPLETING DOSE ESCALATED RADIOTHERAPY IN A COHORT OF INTERMEDIATE RISK PROSTATE CANCER PATIENTS

【24h】

ROBUSTNESS OF THE PHOENIX BIOCHEMICAL FAILURE DEFINITION 10 YEARS AFTER COMPLETING DOSE ESCALATED RADIOTHERAPY IN A COHORT OF INTERMEDIATE RISK PROSTATE CANCER PATIENTS

机译：在完成剂量升级的中间风险前列腺癌患者中，在完成剂量升级的放射治疗后10年的植物生物化学衰竭定义的鲁棒性

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology》 |2019年第2019期|共2页
作者
Aljawi Ghufran; Busca Ionut; MacRae Robert; Eapon Libni;
展开▼
作者单位

Univ Ottawa Ottawa ON Canada;

Univ Ottawa Ottawa ON Canada;

Univ Ottawa Ottawa ON Canada;

Univ Ottawa Ottawa ON Canada;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Robustness of the Phoenix Biochemical Failure Definition 10 Years after Completing Dose Escalated Radiotherapy in a Cohort of Intermediate Risk Prostate Cancer Patients [J] . Aljawi G. A., Busca I., MacRae R. M., International Journal of Radiation Oncology, Biology, Physics . 2019,第1Suppla期

机译：凤凰生化失效定义的鲁棒性10年在完成剂量升级的中间风险前列腺癌患者中的放射治疗后10年
2. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. [J] . Martinez AA, Gonzalez J, Ye H, International Journal of Radiation Oncology, Biology, Physics . 2011,第2期

机译：对于使用超分割高剂量率增强和外照射治疗的中高危前列腺癌患者，剂量递增可改善10年后与癌症相关的事件。
3. Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients [J] . MarinaO., GustafsonG.S., KestinL.L., Brachytherapy . 2014,第1期

机译：在现代的中危前列腺癌患者队列中，以剂量为导向，以图像为导向的放射疗法与以剂量为导向，高剂量率近距离放射疗法的比较
4. ~(18)F-NaF PET/CT-directed dose escalation in stereotactic body radiotherapy for spine oligometastases from prostate cancer [C] . L. Wu, S.A. Kwee, M. Li World Congress on Medical Physics and Biomedical Engineering . 2015

机译：〜（18）F-NAF PET / CT定向剂量升级在前列腺癌中脊柱脱硫菌的立体定向体放射疗法
5. A comparative study of quality of life in patients with low-and intermediate-risk prostate cancer treated at a single institution: Stereotactic radiotherapy vs. high dose-rate brachytherapy monotherapy vs. high dose-rate brachytherapy boost [D] . Helou, Joelle. 2017

机译：单一机构治疗的中低危前列腺癌患者生活质量的比较研究：立体定向放疗与高剂量率近距离放射疗法单药疗法与高剂量率近距离放射疗法增强
6. The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer: effects of radiation dose escalation [O] . Michelle S Ludwig, Deborah A Kuban, Xianglin L Du, 2015

机译：雄激素剥夺治疗在中危前列腺癌中生化衰竭和远处转移中的作用：放射剂量升高的影响
7. Robustness of the Phoenix Biochemical Failure Definition 10 Years after Completing Dose Escalated Radiotherapy in a Cohort of Intermediate Risk Prostate Cancer Patients [O] . G.A. Aljawi, I. Busca, R.M. MacRae, 2019

机译：凤凰生化失效定义的鲁棒性10年在完成剂量升级的中间风险前列腺癌患者中的放射治疗后10年

ROBUSTNESS OF THE PHOENIX BIOCHEMICAL FAILURE DEFINITION 10 YEARS AFTER COMPLETING DOSE ESCALATED RADIOTHERAPY IN A COHORT OF INTERMEDIATE RISK PROSTATE CANCER PATIENTS

著录项

相似文献

相关主题

期刊订阅